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INTRODUCTION: 
To get sustained release of the drug is aimed to decrease 
the dose and dosing frequency and so its side effects. 
Sustained-release formulations may be administered once 
or twice daily
1
. The multilayered tablet concept has been 
long utilized to develop sustained release formulations. 
Such a tablet has a fast releasing layer and may contain bi- 
or triple layers to sustain the drug release. The 
pharmacokinetic advantage relies on the fact that drug 
release from fast releasing granules leads to a sudden rise 
in the blood concentration. However, the blood level is 
maintained at steady state as the drug is released from the 
sustaining granules. Among the different polymers, 
Eudragit and Hydroxypropylmethylcellulose have been 
used successfully to obtain appropriate sustained release 
matrix formulations. 
Metformin is an antihyperglycemic agent, which improves 
glucose tolerance in patients with type 2 diabetes, lowering 
both basal and postprandial plasma glucose. Metformin is 
not chemically or pharmacologically related to any other 
classes of oral antihyperglycemic agents. Metformin 
decreases hepatic glucose production, decreases intestinal 
absorption of glucose, and improves insulin sensitivity by 
increasing peripheral glucose uptake and utilization. The 
drug also has relatively short plasma elimination half life 
of 1.5 to 4.5 hours
7,8
.So SR products are needed for 
metformin to prolong its duration of action and improve 
patient compliance
2,3
. 
 Pioglitazone, a member of the drug group known as the 
thiazolidinediones or "insulin sensitizers", is not 
chemically or functionally related to the alpha-glucosidase 
inhibitors, the biguanides, or the sulfonylureas. 
Pioglitazone targets insulin resistance and, hence, is used 
alone or in combination with insulin, metformin, or 
asulfonylurea as an antidiabetic agent. pioglitazone both 
enhances tissue sensitivity to insulin and reduces hepatic 
gluconeogenesis. Thus, insulin resistance associated with 
type 2 diabetes mellitus is improved without an increase in 
insulin secretion by pancreatic β cells. 
MATERIAL  
MetforminHCl and pioglitazoneHCl were provided as gift 
sample Bharat PrenteralsLtd. Baroda,India. 
Hydroxypropylmethylcellulosee15, hydroxypropylmethyl-
celluloseK100, carbopol934, ethylcellulose, PVPK30, 
microcrystallinecellulose, sodium bicarbonate, citric acid, 
magnesium stearate and talc of analytical grade were 
purchased from National Chemicals, Mumbai. Isopropyl 
alcohol of analytical grade was purchased from Sigma 
Eldrich, Mumbai and used without any further purification  
METHODS 
Preparation of bilayered tablet: Bilayer tablet of 
MetforminHCl and Pioglitazine was developed in three 
different stages. Sustained release layer of MetforminHCl 
was prepared by wet granulation using solution of 
PVPK30 in isopropyl alcohol and immediate release layer 
of PioglitazoneHCl was optimized separately by direct 
compression technique. After optimization of individual 
layers, the bilayer tablet was prepared where immediate 
release layer was compression coated on optimized tablet 
of MetforminHCl. 
Swelling index: The swelling index of tablets was 
determined in 0.1N HCl (pH 1.2) at room temperature. The 
swollen weight of the tablet was determined at predefined 
time intervals over a period of 10h. The swelling index 
(SI), expressed as a percentage, and was calculated from 
the following equation SI = {(Mt-Mo)/Mo} X 100; Where, 
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SI = Swelling index, Mt = Weight of tablet at time ‘t’and 
Mo = Weight of tablet at time ‘t=0’. 
In-vitro buoyancy studies: In-vitro buoyancy studies were 
performed for all the formulations as per the method 
described by Rosa et al. The randomly selected tablets 
from each formulation were kept in a 100ml beaker 
containing simulated gastric fluid, pH1.2 as per USP. The 
time taken for the tablet to rise to the surface and float was 
taken as floating lag time (FLT). The duration of time the 
dosage form constantly remained on the surface of 
medium was determined as the total floating time (TFT). 
Release rate study: The release rate of MetforminHCl from 
floating tablets was determined USP dissolution testing 
apparatus type I (Basket method) and that of 
PioglitazoneHCl in USP dissolution testing apparatus type 
II. The dissolution test was performed using 900 ml of 
0.1N hydrochloric acid, at 37 ± 0.5°C and 50rpm. A 
sample (5ml) of the solution was withdrawn from the 
dissolution apparatus hourly and the samples were 
replaced with fresh dissolution medium. The samples were 
filtered through a 0.45μ membrane filter and diluted to a 
suitable concentration with 0.1N hydrochloric acid. 
Absorbance of these solutions was measured at 232nm (for 
metforminHCl) and 268nm (for pioglitazoneHCl)  using a 
UV/Visible spectrophotometer. The percentage drug 
release was plotted against time to determine the release 
profile 
RESULTS AND DISCUSSION: 
All the formulations given in table 1 and 3 were 
formulated.Once daily dosage form  of sustained release 
MetforminHCl  and immediate release PioglitazoneHCl 
tablets were formed they were evaluated for various 
physical properties individualy and the values are shown in 
the table 2 and 4 respectively. As swlling polymers are 
used to sustain the release swelling indexes
6
 were obtained 
for 10hrs and their results are given in table 2.Figure 1 and 
2 shows the dissolution profile of MetforminHCl sustained 
release tablets and PioglitazoneHCl immediate release 
tablet. 
Table 1: Formulation table of MetforminHCl sustained release layer 
Ingredients Batch code 
M1 M2  M3 M4 M5 M6 M7 M8 M9 
MetforminHCl 500 500 500 500 500 500 500 500 500 
HPMC E15 150 100 50 50 75 100 150 100 50 
HPMC K100 50 100 150 100 75 50 50 100 150 
Carbopol - - - 50 50 50 50 50 50 
PVPk30 25 25 25 25 25 25 25 25 25 
Sodium Bicarbonate 50 50 50 50 50 50 50 50 50 
Citric acid 15 15 15 15 15 15 15 15 15 
MCC 52 52 52 02 02 02 02 02 02 
Mg. stearate 5 5 5 5 5 5 5 5 5 
Talc 3 3 3 3 3 3 3 3 3 
Total 850 850 850 850 850 850 850 850 850 
Table 2:  Evaluation parameters of metforminHCl SR tablets 
Formulations Friability 
(%) 
Hardness (kg/cm2) 
N=3 
Floating lag time 
(sec) N=3 
Total floating 
time* (hrs) 
Swelling Index 
(%) after 10 hrs 
M1 0.72 7.5±0.12 30±3.03 10hr 92.2 
M2 0.54 8.1±0.20 38±2.24 10hr 94.33 
M3 0.63 7.6±0.18 44±3.82 10hr 96.43 
M4 0.82 7.5±0.25 55±2.47 10hr 102.7 
M5 0.64 8.0±0.25 61±1.85 10hr 101.7 
M6 0.83 7.6±0.25 66±3.27 10hr 99.58 
M7 0.59 8.5±0.35 68±2.11 10hr 124.8 
M8 0.79 8.4±0.75 70±3.51 10hr 126.9 
M9 0.28 7.5±0.52 73±4.82 10hr 127.9 
* The study of total floating time was conducted for 10hr only. 
All the nine batches were subjected to in-vitro dissolution 
Table 3: Formulation table of PioglitazoneHCl IR layer 
Ingredients 
Batch Code 
P1 P2 P3 
PioglitazoneHCl 15 15 15 
Crosspovidone 3 5 7 
MCC 77 75 73 
Mg stearate 1 1 1 
Talc 2 2 2 
Color 2 2 2 
Total 100 100 100 
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Figure 1 Dissolution comparision of all metformin sustained release tablet 
From above all formulations of metformin tablets M9 showing desirable sustained release for 10 hrs so it is concluded as 
optimized batch. 
Table 4:  Evaluation parameters of PioglitazoneHCl IR tablets: 
Formulations Friability (%) Hardness (kg/cm2) 
N=3 
DT 
(sec) 
P1 0.72 4.5±0.10 256 
P2 0.54 5.1±0.14 260 
P3 0.63 4.6±0.11 259 
 
For immediate layer of PioglitazoneHCl, we used 
crospovidone as superdisintegrant. In above formulations 
P1, P2 and P3 crospovidone was used in concentration of 
3%, 5%, and 7% respectively.   
From it can be told that formulation P2 and P3 released 
85% of drug within 15 min which is desirable. Hence 
Batch P2 with 5% of crospovidone was optimizesd. Here 
5% of crospovidone was selected because it was 
recommended by literature & 7% crospovidone was 
rejected. 
The drug release data of MetforminHCl and 
PioglitazoneHCl were fitted to models representing zero 
order, first order, Higuchi’s and Korsmeyer’s equation9 
kinetics to know the release mechanisms. The data were 
processed for regression analysis using MS EXCEL 2007 
statistical function. The results are shown in Table 5 .  
In the present study, in vitro release profiles could be best 
expressed by Higuchi’s equation as optimized formulation 
(M9P2) showed good linearity (R
2
: 0.975) indicates that 
diffusion is dominant mechanism of drug release with this 
formulation
4,5
. 
After evaluating all the batches M9P2 is optimized and so 
final formulation of bilayer tablet is given in table 7 and its 
evaluation date is given in table 8. 
Table 6: Formulation of Final optimized batch M9P2 
Ingredients Final Batch (mg) 
PioglitazoneHCl 15  
 
Immediate 
release layer 
Crosspovidone 3 
MCC 77 
Mg stearate 1 
Talc 2 
Color 2 
MetforminHCl 500  
 
 
 
 
Sustained 
release layer 
HPMC E15 50 
HPMC K100 150 
Carbopol 50 
PVPk30 25 
Sodium Bicarbonate 50 
Citric acid 15 
MCC 02 
Mg. stearate 5 
Talc 3 
Total 950 
 
Table 5: Analysis of Release Mechanism MetforminHCl of Optimized Batch M12P2 
Formulation 
(M12P2) 
Zero order 
R
2
 
First order 
R
2
 
Higuchi 
R
2
 
Korsmayer Peppas 
R
2
 n 
MetforminHCl 0.951 0.780 0.975 0.96 0.502 
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Figure 2: Dissolution comparision of all pioglitazoneHCl  IR tablets 
Table 7: All data of optimized batch 
Parameters M9 P2 
Friability(%) 0.28 0.54 
Hardness(kg/cm2) (n=3) 7.5±0.52 5.1±0.14 
Desintegration time(sec) - 260 
Floating lag time (sec) (n=3) 73±4.82 - 
Total floating time (hrs) 10 - 
Swelling index(%)after 10 hrs 127.9 - 
Kinetic(value) Higuchi - 
 r
2
=0.975 
Drug release 
After 30 min - 98.10±1.67 
After 10hr 98.82±3.75 - 
 
CONCLUSION: 
HPMCE15, HPMCK100 and carbopol934P were used as 
matrix forming polymer for the preparation of 
MetforminHCl sustained release layer which enabled drug 
release  from 5 to 10hrs in different proportion of matrix 
polymers with near to zero order release profile and 
diffusion as preliminary release mechanism. 
PioglitazoneHCl immediate release layer was prepared 
using crosspovidone in different proportion where 3% was 
found promising which disintegrates completely within 
4min. The core tablet of MetforminHCl in bilayered tablet 
was prepared by wet granulation and immediate release 
layer of PioglitazoneHCl was compression coated on it. 
The optimized bilayered tablet can be used as combination 
therapy for diabetes which reduses dosing frequency and 
improves patient compliance. Pioglitazone release shows 
that the dissolution rate of Pioglitazone can be enhanced 
considerably by using crosspovidone as super disintegrent.  
SR fixed dose bilayer matrix tablets containing 
500mgMetforminHCl as SR from one layer and 15mg 
Piogleitazone as   from another layer can be successfully 
formulated. 
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